^
    Back
    Association details:
    Biomarker:ROS1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2019
    Title:

    ENTRECTINIB IN LOCALLY ADVANCED/METASTATIC ROS1 AND NTRK FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED INTEGRATED ANALYSIS OF STARTRK-2, STARTRK-1 AND ALKA-372-001

    Published date:
    09/29/2019
    Excerpt:
    As of 30 Oct 2018 (additional 5 months’ follow-up), BICR ORR: ROS1+ 79.2% (95% CI 65.9–89.2) and NTRK+ 70.0% (95% CI 34.75–93.33) with complete responses in 5 (9.4%) pts and 1 (10.0%) pt, respectively. In ROS1+ NSCLC, median DOR: 24.6 mo (95% CI 12.6–34.8); in pts with and without baseline CNS disease, ORR was 73.9% (95% CI 51.6–89.8) and 83.3% (95% CI 65.3–94.4); IC ORR was 55.0% (95% CI 31.5–76.9); and median IC DOR was 12.9 mo (95% CI 5.6–not estimable).
    DOI:
    10.1093/annonc/mdz260
    Trial ID:
    STARTRK-2